



Elisa Gallerani

Data di nascita: **1974** | **Nazionalità:** Italiana | **Sesso:** Femminile |

elisa.gallerani@asst-settelaghi.it |

ESPERIENZA LAVORATIVA

01/08/1997 – 31/08/1997 – Ospedale universitario, Linköping, Svezia

CLERKSHIP COME STUDENTE DI MEDICINA INTERNA E PRIMO SOCCORSO

01/03/1998 – 30/03/1998 – Odense, Danimarca

TRAINING COME STUDENTE DI MEDICINA – REPARTO ONCOLOGIA

01/11/1998 – 30/12/1998 – Odense, Danimarca

PERIODO POST LAUREA IN ENDOCRINOLOGIA E PRIMO SOCCORSO

01/01/1999 – 01/01/2000 – Bologna, Italia

SPECIALIZZANDO – REPARTO DI EMATOLOGIA

01/01/2000 – 30/10/2000 – Varese, Italia

SPECIALIZZANDO – OSPEDALE CIRCOLO

01/11/2000 – 30/09/2003 – Mendrisio, Svizzera

SPECIALIZZANDO ASSISTENTE – ISTITUTO DI ONCOLOGIA DELLA SVIZZERA ITALIANA

01/10/2003 – 30/06/2006 – Bellinzona, Svizzera

AIUTO RESPONSABILE – ISTITUTO DI ONCOLOGIA DELLA SVIZZERA ITALIANA

01/07/2006 – 24/12/2006 – Londra, Regno Unito

FELLOWSHIP PER STUDI DI FASE I – ROYAL MARSDEN SUTTON

01/01/2007 – 30/07/2011 – Bellinzona, Svizzera

AIUTO RESPONSABILE – ISTITUTO DI ONCOLOGIA DELLA SVIZZERA ITALIANA

01/08/2011 – 22/05/2017 – Castellanza, Italia

MEDICO SPECIALISTA – MULTIMEDICA

23/05/2017 – 15/11/2018 – Magenta, Italia

INCARICO MEDICO SPECIALISTA – OSPEDALE FORNAROLI

16/11/2018 – ATTUALE – Varese, Italia

MEDICO SPECIALISTA – OSPEDALE CIRCOLO

ISTRUZIONE E FORMAZIONE

01/10/1992 – 15/10/1998 – Bologna, Italia

LAUREA IN MEDICINA E CHIRURGIA – Alma mater Studiorum

01/01/1999 – 01/10/2002 – varese, Italia

SPECIALIZZAZIONE IN ONCOLOGIA – Università dell'Insubria

20/10/2004 – 20/10/2004 – Berna, Svizzera

CERTIFICATO ESAME ESMO

Varese, Italia

DOTTORATO IN ONCOLOGIA SPERIMENTALE – Università dell'Insubria

COMPETENZE LINGUISTICHE

Lingua madre: **ITALIANO**

Altre lingue:

	COMPRENSIONE		ESPRESSIONE ORALE		SCRITTURA
	Ascolto	Lettura	Produzione orale	Interazione orale	
INGLESE	B2	C1	B1	B1	B1

Livelli: A1 e A2: Livello elementare B1 e B2: Livello intermedio C1 e C2: Livello avanzato

■ ALTRO

ESMO membership

IBCSG membership

■ PUBBLICAZIONI

Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?

Anticancer Drugs. 2020 Jun;31(5):528-532.
2020

Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers. doi: 10.1016/j.breast.2019.07.001. Epub 2019 Jul 10. PMID: 31362134.

Breast. 2019 Oct;47:85-92.
2019

Il trattamento del carcinoma mammario nell'era degli inibitori CDK4/6

Expert Series Anno 12 n2, 2022
2022

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? . doi: 10.1016/j.breast.2015.01.005. Epub 2015 Feb 4. PMID: 25662412.

Breast. 2015 Jun;24(3):201-7
2015

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

Breast Cancer Res Treat. 2016 Jul;158(2):323-31.
2016
In affiliation as participating center on behalf of IBCSG

Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers.

Cancer Immunol Res. 2016 Jan;4(1):18-25.
2016

Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series.

Int J Clin Oncol. 2015 Feb;20(1):90-4.
2015

28/30/2021

Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

Clin Cancer Res. 2014 Nov 15;20(22):5663-71.
2015

T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.

J Transl Med. 2013 Jan 7;11:5.
2013

Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.

Cancer Immunol Immunother. 2014 Apr;63(4):381-94.
2014

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.

Eur J Cancer. 2013 Jan;49(2):290-6.
2013

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

J Clin Oncol. 2012 Mar 20;30(9):996-1004.
2012

Axillary apocrine carcinoma with brain metastases.

J Clin Oncol. 2007 Dec 10;25(35):5655-6.
2007

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.

Lung Cancer. 2011 Jun;72(3):378-83.
2011

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.

Eur J Cancer. 2013 Jan;49(1):35-44.
2013

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.

Invest New Drugs. 2013 Oct;31(5):1236-43.
2013

Inpatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

J Clin Oncol. 2012 Aug 10;30(23):2861-8.
2012

A phase I study of the oral platinum agent satraplatin in combination with oral vinorelbine in patients with advanced solid malignancies.

Onkologie. 2013;36(1-2):40-5.
2013

A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.

Acta Oncol. 2011 Oct;50(7):1105-10.
2011

Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab.

Eur J Haematol. 2006 Dec;77(6):527-9.
2006

Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n. 196 - "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 - "Regolamento europeo sulla protezione dei dati personali".

28/JUN) 2022